MX2022002723A - Receptores de antigeno dimerico (dar) que se enlazan a bcma. - Google Patents

Receptores de antigeno dimerico (dar) que se enlazan a bcma.

Info

Publication number
MX2022002723A
MX2022002723A MX2022002723A MX2022002723A MX2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A
Authority
MX
Mexico
Prior art keywords
dar
antigen receptors
dimeric
antigen
dimeric antigen
Prior art date
Application number
MX2022002723A
Other languages
English (en)
Spanish (es)
Inventor
Gunnar F Kaufmann
Henry Hongjun Ji
Wenzhong Guo
Yanliang Zhang
Bei Bei Ding
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2022002723A publication Critical patent/MX2022002723A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022002723A 2019-09-05 2020-09-04 Receptores de antigeno dimerico (dar) que se enlazan a bcma. MX2022002723A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962896190P 2019-09-05 2019-09-05
US201962896990P 2019-09-06 2019-09-06
US201962910341P 2019-10-03 2019-10-03
US201962943069P 2019-12-03 2019-12-03
US202063030145P 2020-05-26 2020-05-26
PCT/US2020/049538 WO2021046445A1 (en) 2019-09-05 2020-09-04 Dimeric antigen receptors (dar) that bind bcma

Publications (1)

Publication Number Publication Date
MX2022002723A true MX2022002723A (es) 2022-03-22

Family

ID=74852154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002723A MX2022002723A (es) 2019-09-05 2020-09-04 Receptores de antigeno dimerico (dar) que se enlazan a bcma.

Country Status (10)

Country Link
US (1) US20220251168A1 (enExample)
EP (1) EP4025227A4 (enExample)
JP (1) JP2022546577A (enExample)
KR (1) KR20220057598A (enExample)
CN (1) CN114650829A (enExample)
AU (1) AU2020341712A1 (enExample)
CA (1) CA3149867A1 (enExample)
IL (1) IL291076A (enExample)
MX (1) MX2022002723A (enExample)
WO (1) WO2021046445A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질
EP4139345A1 (en) 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
EP4326292A4 (en) * 2021-04-23 2025-03-26 Vivasor, Inc. Dimeric antigen receptors (dars) that bind gd2
IL311141A (en) * 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
CN117986387A (zh) * 2023-05-31 2024-05-07 四川大学华西医院 一种新型小型化car设计及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051037A1 (en) * 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
EP3842448A1 (en) * 2015-05-15 2021-06-30 City of Hope Chimeric antigen receptor compositions
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
MX2018004721A (es) * 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
AU2018290272A1 (en) * 2017-06-21 2020-01-30 Gsbio, Llc Heterodimeric bispecific antibodies
SG11202003501XA (en) * 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AU2019231315A1 (en) * 2018-03-09 2020-09-17 Vivasor, Inc. Dimeric antigen receptors (DAR)
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질

Also Published As

Publication number Publication date
KR20220057598A (ko) 2022-05-09
AU2020341712A1 (en) 2022-03-31
EP4025227A4 (en) 2023-11-01
JP2022546577A (ja) 2022-11-04
IL291076A (en) 2022-05-01
EP4025227A1 (en) 2022-07-13
CA3149867A1 (en) 2021-03-11
CN114650829A (zh) 2022-06-21
WO2021046445A1 (en) 2021-03-11
US20220251168A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
MX2022002723A (es) Receptores de antigeno dimerico (dar) que se enlazan a bcma.
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
PE20210652A1 (es) Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
CO2021006911A2 (es) Anticuerpos biespecíficos anti-pd-l1/anti-4-1bb y usos de los mismos
PE20241349A1 (es) Anticuerpos de union a cd3
PE20241170A1 (es) Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3
AR124692A2 (es) Anticuerpos anti-cd40 y sus usos
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
CO2019006565A2 (es) Novedoso conjugado de amanitina
AR085404A1 (es) Proteinas de union a antigeno
MX2019011986A (es) Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
CL2017000250A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
CO2018002360A2 (es) Anticuerpos biespecíficos contra el a-beta humano y el receptor de transferrina humano y métodos de uso
MX2020013606A (es) Constructos de anticuerpos multiespecificos.
EA202190542A1 (ru) Сконструированные биспецифические белки
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
ECSP21052180A (es) Receptores que ofrecen coestimulación específica para terapia adoptiva de células
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos